United States - English - NLM (National Library of Medicine)

sandoz inc - lansoprazole (unii: 0k5c5t2qpg) (lansoprazole - unii:0k5c5t2qpg) - lansoprazole 30 mg - the components in lansoprazole delayed-release capsules usp, 30 mg, amoxicillin capsules usp, 500 mg, and clarithromycin tablets usp, 500 mg (lansoprazole, amoxicillin, and clarithromycin) are indicated for the treatment of patients with h. pylori infection and duodenal ulcer disease (active or one-year history of a duodenal ulcer) to eradicate h. pylori . eradication of h. pylori has been shown to reduce the risk of duodenal ulcer recurrence (see clinical studies and dosage and administration ). to reduce the development of drug-resistant bacteria and maintain the effectiveness of lansoprazole delayed-release capsules usp, 30 mg, amoxicillin capsules usp, 500 mg, and clarithromycin tablets usp, 500 mg and other antibacterial drugs, lansoprazole delayed-release capsules usp, 30 mg, amoxicillin capsules usp, 500 mg, and clarithromycin tablets usp, 500 mg should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibil

United States - English - NLM (National Library of Medicine)

prasco laboratories - lansoprazole (unii: 0k5c5t2qpg) (lansoprazole - unii:0k5c5t2qpg) - lansoprazole 30 mg - the components in lansoprazole/amoxicillin/clarithromycin are indicated for the treatment of patients with h. pylori infection and duodenal ulcer disease (active or one-year history of a duodenal ulcer) to eradicate h. pylori. eradication of h. pylori has been shown to reduce the risk of duodenal ulcer recurrence (see clinical studies and dosage and administration) . to reduce the development of drug-resistant bacteria and maintain the effectiveness of lansoprazole/amoxicillin/clarithromycin and other antibacterial drugs, lansoprazole/amoxicillin/clarithromycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. lansoprazole/amoxicillin/clarithromycin is contraindicated in p

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - lansoprazole, quantity: 15 mg - tablet, orally disintegrating - excipient ingredients: glyceryl monostearate; citric acid; hyprolose; purified water; purified talc; aspartame; polysorbate 80; methacrylic acid - ethyl acrylate copolymer (1:1); hypromellose; polyacrylate dispersion (30 per cent); titanium dioxide; crospovidone; macrogol 6000; microcrystalline cellulose; iron oxide yellow; iron oxide red; mannitol; triethyl citrate; magnesium stearate; magnesium carbonate hydrate; xylitol; calcium hydrogen phosphate; flavour - adults:,1.healing and long-term management of reflux oesophagitis.,2.healing and long-term management for patients with duodenal ulcer.,3.healing of benign gastric ulcer. patients whose gastric or duodenal ulcer is not associated with ingestion of non-steroidal anti-inflammatory drugs require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence.,4.lansoprazole is also effective in patients with benign peptic lesions that do not respond to h2-receptor antagonists.,5.eradication of h. pylori from the upper gastrointestinal tract in patients with peptic ulcer or chronic gastritis when used in combination with appropriate antibiotics (see clinical trials).,6.relief of reflux-like and/or ulcer-like symptoms associated with acid-related dyspepsia.,paediatric patients 6 to 17 years of age.,1.treatment of gastro-oesophageal reflux disease, including all grades of oesophagitis.,2.healing of erosive oesophagitis.

Ireland - English - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd t/a gerard laboratories - lansoprazole - capsules gastro-resistant - 30 milligram - lansoprazole

Ireland - English - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd t/a gerard laboratories - lansoprazole - capsules gastro-resistant - 15 milligram - lansoprazole

Ireland - English - HPRA (Health Products Regulatory Authority)

wpr healthcare limited - lansoprazole - capsules gastro-resistant - 15 milligram - lansoprazole

Ireland - English - HPRA (Health Products Regulatory Authority)

wpr healthcare limited - lansoprazole - capsules gastro-resistant - 30 milligram - lansoprazole

Malta - English - Medicines Authority

generics uk limited - lansoprazole - orodispersible tablet - lansoprazole 15 mg - drugs for acid related disorders

Malta - English - Medicines Authority

generics uk limited - lansoprazole - orodispersible tablet - lansoprazole 30 mg - drugs for acid related disorders

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - lansoprazole, quantity: 30 mg - tablet, orally disintegrating - excipient ingredients: iron oxide yellow; hyprolose; crospovidone; microcrystalline cellulose; iron oxide red; titanium dioxide; polyacrylate dispersion (30 per cent); methacrylic acid - ethyl acrylate copolymer (1:1); polysorbate 80; magnesium stearate; aspartame; triethyl citrate; mannitol; citric acid; glyceryl monostearate; magnesium carbonate hydrate; hypromellose; macrogol 6000; purified talc; purified water; flavour; xylitol; calcium hydrogen phosphate - adults:,1.healing and long-term management of reflux oesophagitis.,2.healing and long-term management for patients with duodenal ulcer.,3.healing of benign gastric ulcer. patients whose gastric or duodenal ulcer is not associated with ingestion of non-steroidal anti-inflammatory drugs require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence.,4.lansoprazole is also effective in patients with benign peptic lesions that do not respond to h2-receptor antagonists.,5.eradication of h. pylori from the upper gastrointestinal tract in patients with peptic ulcer or chronic gastritis when used in combination with appropriate antibiotics (see clinical trials).,6.relief of reflux-like and/or ulcer-like symptoms associated with acid-related dyspepsia.,paediatric patients 6 to 17 years of age.,1.treatment of gastro-oesophageal reflux disease, including all grades of oesophagitis.,2.healing of erosive oesophagitis.